Top

Published in:

01-03-2014 | Original Research

EGFR intron-1 CA repeat polymorphism is a predictor of relapse and survival in complete resected only surgically treated esophageal cancer

Authors: Yogesh K. Vashist, Florian Trump, Florian Gebauer, Asad Kutup, Cenap Güngör, Viacheslav Kalinin, Rather Muddasar, Eik Vettorazzi, Emre F. Yekebas, Burkhard Brandt, Klaus Pantel, Jakob R. Izbicki

Published in: Targeted Oncology | Issue 1/2014

Abstract

Basal transcription regulation of the epidermal growth factor receptor is dependent upon a CA simple sequence repeat polymorphism in the intron-1 (CA-SSR-1). Here, we evaluate the role of CA-SSR-1 in complete resected esophageal cancer (EC) patients without neoadjuvant or adjuvant treatment. Genomic DNA was extracted from peripheral blood leukocytes of 241 patients. To determine the number of the CA repeats in the CA-SSR-1, DNA was amplified by polymerase chain reaction and sequenced. The results were correlated with clinicopathological parameters and clinical outcome. Three genotypes were defined based on cut-off points for short allele (S) with ≤18 and long allele (L) >18 CA repeats. A steadily increasing risk was evident between LL, SL, and SS genotype for larger tumor size, presence of lymph node metastases, and disseminated tumor cells in bone marrow as well as tumor recurrence (P < 0.001, chi-square test). A gradual decrease in disease-free and overall survival (OS) was present among LL, SL, and SS patients (P < 0.001, log-rank test). The different outcomes were also evident in nodal status and histological type adjusted subgroup analyses. CA-SSR-1 was identified as the strongest independent prognosticator of tumor recurrence and OS (P < 0.001, Cox regression analysis). CA-SSR-1 is a strong predictive factor for tumor recurrence and overall survival in patients with complete resected esophageal cancer without neoadjuvant or adjuvant therapy.

Malthaner RA, Wong RK, Rumble RB, Zuraw L (2004) Neoadjuvant or adjuvant therapy for resectable esophageal cancer: a systematic review and meta-analysis. BMC Med 2:35PubMedCentralPubMedCrossRef

Peyre CG, Hagen JA, DeMeester SR et al (2008) Predicting systemic disease in patients with esophageal cancer after esophagectomy: a multinational study on the significance of the number of involved lymph nodes. Ann Surg 248:979–985PubMedCrossRef

Malthaner R, Wong RK, Spithoff K (2010) Preoperative or postoperative therapy for resectable oesophageal cancer: an updated practice guideline. Clin Oncol (R Coll Radiol) 22:250–256

Karamouzis MV, Grandis JR, Argiris A (2007) Therapies directed against epidermal growth factor receptor in aerodigestive carcinomas. Jama 298:70–82PubMedCrossRef

Tabernero J, Macarulla T, Ramos FJ, Baselga J (2005) Novel targeted therapies in the treatment of gastric and esophageal cancer. Ann Oncol 16:1740–1748PubMedCrossRef

Ferry DR, Anderson M, Beddard K et al (2007) A phase II study of gefitinib monotherapy in advanced esophageal adenocarcinoma: evidence of gene expression, cellular, and clinical response. Clin Cancer Res 13:5869–5875PubMedCrossRef

Gibault L, Metges JP, Conan-Charlet V et al (2005) Diffuse EGFR staining is associated with reduced overall survival in locally advanced oesophageal squamous cell cancer. Br J Cancer 93:107–115PubMedCentralPubMedCrossRef

Wang KL, Wu TT, Choi IS et al (2007) Expression of epidermal growth factor receptor in esophageal and esophagogastric junction adenocarcinomas: association with poor outcome. Cancer 109:658–667PubMedCrossRef

Gusterson BA, Hunter KD (2009) Should we be surprised at the paucity of response to EGFR inhibitors? Lancet Oncol 10:522–527PubMedCrossRef

10.

Linardou H, Dahabreh IJ, Bafaloukos D et al (2009) Somatic EGFR mutations and efficacy of tyrosine kinase inhibitors in NSCLC. Nat Rev Clin Oncol 6:352–366PubMedCrossRef

11.

Janmaat ML, Gallegos-Ruiz MI, Rodriguez JA et al (2006) Predictive factors for outcome in a phase II study of gefitinib in second-line treatment of advanced esophageal cancer patients. J Clin Oncol 24:1612–1619PubMedCrossRef

12.

Rao S, Starling N, Cunningham D et al (2008) Phase I study of epirubicin, cisplatin and capecitabine plus matuzumab in previously untreated patients with advanced oesophagogastric cancer. Br J Cancer 99:868–874PubMedCentralPubMedCrossRef

13.

Javle M, Pande A, Iyer R et al (2008) Pilot study of gefitinib, oxaliplatin, and radiotherapy for esophageal adenocarcinoma: tissue effect predicts clinical response. Am J Clin Oncol 31:329–334PubMedCrossRef

14.

Hanawa M, Suzuki S, Dobashi Y et al (2006) EGFR protein overexpression and gene amplification in squamous cell carcinomas of the esophagus. Int J Cancer 118:1173–1180PubMedCrossRef

15.

Inada S, Koto T, Futami K et al (1999) Evaluation of malignancy and the prognosis of esophageal cancer based on an immunohistochemical study (p53, E-cadherin, epidermal growth factor receptor). Surg Today 29:493–503PubMedCrossRef

16.

Sunpaweravong P, Sunpaweravong S, Puttawibul P et al (2005) Epidermal growth factor receptor and cyclin D1 are independently amplified and overexpressed in esophageal squamous cell carcinoma. J Cancer Res Clin Oncol 131:111–119PubMedCrossRef

17.

Brandt B, Meyer-Staeckling S, Schmidt H et al (2006) Mechanisms of egfr gene transcription modulation: relationship to cancer risk and therapy response. Clin Cancer Res 12:7252–7260PubMedCrossRef

18.

Packeisen J, Nakachi K, Boecker W et al (2005) Cytogenetic differences in breast cancer samples between German and Japanese patients. J Clin Pathol 58:1101–1103PubMedCentralPubMedCrossRef

19.

Gebhardt F, Burger H, Brandt B (2000) Modulation of EGFR gene transcription by a polymorphic repetitive sequence—a link between genetics and epigenetics. Int J Biol Markers 15:105–110PubMed

20.

Gebhardt F, Zanker KS, Brandt B (1999) Modulation of epidermal growth factor receptor gene transcription by a polymorphic dinucleotide repeat in intron 1. J Biol Chem 274:13176–13180PubMedCrossRef

21.

Suzuki M, Kageyama S, Shinmura K et al (2008) Inverse relationship between the length of the EGFR CA repeat polymorphism in lung carcinoma and protein expression of EGFR in the carcinoma. J Surg Oncol 98:457–461PubMedCrossRef

22.

Dubey S, Stephenson P, Levy DE et al (2006) EGFR dinucleotide repeat polymorphism as a prognostic indicator in non-small cell lung cancer. J Thorac Oncol 1:406–412PubMedCrossRef

23.

Kersting C, Agelopoulos K, Schmidt H et al (2008) Biological importance of a polymorphic CA sequence within intron 1 of the epidermal growth factor receptor gene (EGFR) in high grade central osteosarcomas. Genes Chromosom Cancer 47:657–664PubMedCrossRef

24.

Liu W, Wu X, Zhang W et al (2007) Relationship of EGFR mutations, expression, amplification, and polymorphisms to epidermal growth factor receptor inhibitors in the NCI60 cell lines. Clin Cancer Res 13:6788–6795PubMedCrossRef

25.

Tzeng CW, Frolov A, Frolova N et al (2007) Pancreatic cancer epidermal growth factor receptor (EGFR) intron 1 polymorphism influences postoperative patient survival and in vitro erlotinib response. Ann Surg Oncol 14:2150–2158PubMedCrossRef

26.

Zhou Q, Cheung YB, Jada SR et al (2006) EGFR Intron 1 polymorphism in Asian Populations and its correlation with EGFR gene expression and amplification in breast tumor tissues. Cancer Biol Ther 5:1445–1449PubMedCrossRef

27.

Huang CL, Yang CH, Yeh KH et al (2009) EGFR intron 1 dinucleotide repeat polymorphism is associated with the occurrence of skin rash with gefitinib treatment. Lung Cancer 64:346–351PubMedCrossRef

28.

Tiseo M, Capelletti M, De Palma G et al (2008) Epidermal growth factor receptor intron-1 polymorphism predicts gefitinib outcome in advanced non-small cell lung cancer. J Thorac Oncol 3:1104–1111PubMedCrossRef

29.

Buerger H, Gebhardt F, Schmidt H et al (2000) Length and loss of heterozygosity of an intron 1 polymorphic sequence of egfr is related to cytogenetic alterations and epithelial growth factor receptor expression. Cancer Res 60:854–857PubMed

30.

Fehm T, Braun S, Muller V et al (2006) A concept for the standardized detection of disseminated tumor cells in bone marrow from patients with primary breast cancer and its clinical implementation. Cancer 107:885–892PubMedCrossRef

31.

Dragovich T, Campen C (2009) Anti-EGFR-targeted therapy for esophageal and gastric cancers: an evolving concept. J Oncol 2009:804108PubMedCentralPubMedCrossRef

32.

Hynes NE, MacDonald G (2009) ErbB receptors and signaling pathways in cancer. Curr Opin Cell Biol 21:177–184PubMedCrossRef

33.

Allegra CJ, Jessup JM, Somerfield MR et al (2009) American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy. J Clin Oncol 27:2091–2096PubMedCrossRef

34.

Eberhard DA, Giaccone G, Johnson BE (2008) Biomarkers of response to epidermal growth factor receptor inhibitors in Non-Small-Cell Lung Cancer Working Group: standardization for use in the clinical trial setting. J Clin Oncol 26:983–994PubMedCrossRef

35.

Engelman JA, Janne PA (2008) Mechanisms of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer. Clin Cancer Res 14:2895–2899PubMedCrossRef

36.

Langer CJ (2008) Targeted therapy in head and neck cancer: state of the art 2007 and review of clinical applications. Cancer 112:2635–2645PubMedCrossRef

37.

Linardou H, Dahabreh IJ, Kanaloupiti D et al (2008) Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer. Lancet Oncol 9:962–972PubMedCrossRef

38.

Buerger H, Packeisen J, Boecker A et al (2004) Allelic length of a CA dinucleotide repeat in the egfr gene correlates with the frequency of amplifications of this sequence—first results of an inter-ethnic breast cancer study. J Pathol 203:545–550PubMedCrossRef

39.

Brandt B, Hermann S, Straif K et al (2004) Modification of breast cancer risk in young women by a polymorphic sequence in the egfr gene. Cancer Res 64:7–12PubMedCrossRef

40.

Boone J, van Hillegersberg R, Offerhaus GJ et al (2009) Targets for molecular therapy in esophageal squamous cell carcinoma: an immunohistochemical analysis. Dis Esophagus 22:496–504

41.

Ressiot E, Dahan L, Liprandi A et al (2008) Predictive factors of the response to chemoradiotherapy in esophageal cancer. Gastroenterol Clin Biol 32:567–577PubMedCrossRef

42.

Wei Q, Chen L, Sheng L et al (2007) EGFR, HER2 and HER3 expression in esophageal primary tumours and corresponding metastases. Int J Oncol 31:493–499PubMed

43.

Mariette C, Piessen G, Triboulet JP (2007) Therapeutic strategies in oesophageal carcinoma: role of surgery and other modalities. Lancet Oncol 8:545–553PubMedCrossRef

44.

Quiros RM, Bui CL (2009) Multidisciplinary approach to esophageal and gastric cancer. Surg Clin N Am 89:79–96, viiiPubMedCrossRef

45.

McShane LM, Altman DG, Sauerbrei W et al (2005) Reporting recommendations for tumor marker prognostic studies. J Clin Oncol 23:9067–9072PubMedCrossRef

46.

Sauter G, Simon R, Hillan K (2003) Tissue microarrays in drug discovery. Nat Rev Drug Discov 2:962–972PubMedCrossRef

47.

Roetger A, Brandt B, Barnekow A (1997) Competitive-differential polymerase chain reaction for gene dosage estimation of erbB-1 (egfr), erbB-2, and erbB-3 oncogenes. DNA Cell Biol 16:443–448PubMedCrossRef

48.

Pantel K, Brakenhoff RH (2004) Dissecting the metastatic cascade. Nat Rev Cancer 4:448–456PubMedCrossRef

49.

Pantel K, Brakenhoff RH, Brandt B (2008) Detection, clinical relevance and specific biological properties of disseminating tumour cells. Nat Rev Cancer 8:329–340PubMedCrossRef

50.

Pantel K, Cote RJ, Fodstad O (1999) Detection and clinical importance of micrometastatic disease. J Natl Cancer Inst 91:1113–1124PubMedCrossRef

Title: EGFR intron-1 CA repeat polymorphism is a predictor of relapse and survival in complete resected only surgically treated esophageal cancer
Authors: Yogesh K. Vashist
Florian Trump
Florian Gebauer
Asad Kutup
Cenap Güngör
Viacheslav Kalinin
Rather Muddasar
Eik Vettorazzi
Emre F. Yekebas
Burkhard Brandt
Klaus Pantel
Jakob R. Izbicki
Publication date: 01-03-2014
Publisher: Springer International Publishing
Published in: Targeted Oncology / Issue 1/2014
Print ISSN: 1776-2596
Electronic ISSN: 1776-260X
DOI: https://doi.org/10.1007/s11523-013-0260-2

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2014

Comparison of acute toxicity and mortality after two different dosing regimens of high-dose interleukin-2 for patients with metastatic melanoma

Caffeic acid phenylethyl ester and MG132, two novel nonconventional chemotherapeutic agents, induce apoptosis of human leukemic cells by disrupting mitochondrial function

Trends in cancer-targeted antibody–drug conjugates

Recommendations for the clinical and radiological evaluation of response to treatment in metastatic renal cell cancer

Subcutaneous trastuzumab: a review of its use in HER2-positive breast cancer

Partial response of a rare malignant metastatic diffuse tenosynovial giant cell tumor with benign histologic features, treated with SCH 717–454, an insulin growth factor receptor inhibitor, in combination with everolimus, an MTOR inhibitor

Keynote webinar | Spotlight on antibody–drug conjugates in cancer